Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 vs Semaglutide in Type 2 Diabetes Mellitus
NCT06649344Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HRS9531 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Change in Glycated Hemoglobin (HbA1c) at 36 weeks. Started Oct 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06649344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649344.